Drug Trial Radar · NCT02138825
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
Last checked: Nov 20, 2026Latest source record: Dec 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
147
Actual
Start
Jun 4, 2014
Primary completion
May 5, 2016
Study completion Sep 14, 2016
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- May 15, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).
Conditions
- Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)Drug
Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
PlaceboDrug
Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in 6 Minute Walking Distance (6MWD) From Baseline to Week 26Time frame: Baseline to 26 weeks
Locations
93 sites in 21 countries. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
Site not named
San Francisco, California
Site not named
Aurora, Colorado
Site not named
Miami, Florida
Site not named
Orlando, Florida
Via Christi Clinic
Wichita, Kansas
Site not named
Louisville, Kentucky
Columbia University Medical Center
New York, New York
Site not named
Durham, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Falls Church, Virginia
Site not named
Mar del Plata, Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Godoy Cruz, Mendoza Province, Argentina
Site not named
San Miguel de Tucumán, Tucumán Province, Argentina
Site not named
Camperdown, New South Wales, Australia
Site not named
Darlinghurst, New South Wales, Australia
Site not named
Sydney, New South Wales, Australia
Site not named
Chermside, Queensland, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Prahran, Victoria, Australia
Site not named
Murdoch, Western Australia, Australia
Site not named
Leuven, Belgium
Site not named
Québec, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Bogotá, Colombia
Site not named
Bogotá, Bogota D.C., Colombia
Site not named
Floridablanca-Bucaramanga, Santander Department, Colombia
Site not named
Cali, Valle del Cauca Department, Colombia
Site not named
Aarhus N, Denmark
Site not named
Bron, France
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.